Candel Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for CADL, updated each market day.
CADL AI Sentiment
AI predicts Candel Therapeutics, Inc. Common Stock stock is likely to increase over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Candel Therapeutics, Inc. Common Stock
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Sector
Exchange
Market Cap
$351,585,249
Cap Tier
Employees
55
Headquarters
NEEDHAM, MA
Listed Since
July 27, 2021
Website
CADL Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
CADL Volatility
Candel Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
